D09- in situ neoplasms
Tautopathic treatment of cancer patients
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Registry summary (technical)
A multicentric, double-blind, randomized, placebo-controlled, phase III study to evaluate the role of potentized (Tautopathy) form of chemotherapy in patients to determine the reduction in the pre-identified side effects of non-potentised chemotherapy drugs cisplatin, docetaxel, paclitaxel, carboplatin, epirubicin, gemcitabine, cyclophosphamide and adriamycin on cancer patients to enhance tolerance to chemotherapy regimen.
Sponsor: Central Council for Research in Homoeopathy
CTRI/2025/03/082132 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 3 Aug 2026 · read by us 5 Nov 2026